Combination of Human Fas （CD95/Apo-1） Ligand with Adriamycin Significantly Enhances the Efficacy of Antitumor Response

The prognosis of hepatocellular carcinoma （HCC） is poor, even with the combined treatment of curative resection and adjuvant chemoradiotherapy. To solve this problem, many biologic therapies have been investigated. Fas ligand （FasL, CD95L） is mainly expressed in activated T lymphocytes and natural k...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cellular & molecular immunology 2009, Vol.6 (3), p.167-174
1. Verfasser:	Zhongchen Liu Ruizhen Liu Jinhua Qiu Ping Yin Fanghong Luo Jinhua Su Wenzhu Li Caixia Chen Xin Fan Jiakai Zhang Guohong Zhuang
Format:	Artikel
Sprache:	eng
Schlagworte:	FasL 抗肿瘤 脂肪酸 阿霉素
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!